Matching articles for "idarucizumab"
Balfaxar: Another Four-Factor PCC for Warfarin Reversal
The Medical Letter on Drugs and Therapeutics • February 19, 2024; (Issue 1696)
Balfaxar (Octapharma), a human plasma-derived
four-factor prothrombin complex concentrate (PCC),
has been approved by the FDA for rapid reversal of
warfarin anticoagulation in adults who require an
urgent...
Balfaxar (Octapharma), a human plasma-derived
four-factor prothrombin complex concentrate (PCC),
has been approved by the FDA for rapid reversal of
warfarin anticoagulation in adults who require an
urgent surgical/invasive procedure. It is the second
four-factor PCC to become available in the US;
Kcentra, which has been available since 2013, is
approved for the same indication and for urgent
reversal of warfarin anticoagulation in adults with
acute major bleeding. Balfaxar is marketed in Canada
and Europe as Octaplex.
Treatment of Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • January 8, 2024; (Issue 1693)
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of...
Atrial fibrillation (AF) is the most common arrhythmia
in the world. Risk factor modification, anticoagulation,
rhythm control, and rate control are the four pillars
of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines
on management of AF were updated recently.
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • July 25, 2022; (Issue 1655)
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines for
treatment of VTE were updated in 2020 and 2021.
Drugs for Atrial Fibrillation
The Medical Letter on Drugs and Therapeutics • September 9, 2019; (Issue 1580)
Treatment of atrial fibrillation includes anticoagulation,
rate control, and rhythm control. US guidelines were
recently...
Treatment of atrial fibrillation includes anticoagulation,
rate control, and rhythm control. US guidelines were
recently updated.
Andexxa - An Antidote for Apixaban and Rivaroxaban
The Medical Letter on Drugs and Therapeutics • June 18, 2018; (Issue 1549)
Coagulation factor Xa (recombinant), inactivated-zhzo
(andexanet alfa; Andexxa – Portola) has received
accelerated approval from the FDA for urgent reversal
of the anticoagulant effect of the direct factor...
Coagulation factor Xa (recombinant), inactivated-zhzo
(andexanet alfa; Andexxa – Portola) has received
accelerated approval from the FDA for urgent reversal
of the anticoagulant effect of the direct factor Xa
inhibitors apixaban (Eliquis) and rivaroxaban (Xarelto).
Andexanet alfa is the second antidote for a direct oral
anticoagulant to become available in the US, and the
fi rst for factor Xa inhibitors. Idarucizumab (Praxbind)
was approved in 2015 for reversal of the anticoagulant
effect of the direct thrombin inhibitor dabigatran
etexilate (Pradaxa). Andexanet alfa has not been
approved to date for reversal of anticoagulation with
the direct factor Xa inhibitors edoxaban (Savaysa) or
betrixaban (Bevyxxa).
Drugs for Treatment and Prevention of Venous Thromboembolism
The Medical Letter on Drugs and Therapeutics • March 12, 2018; (Issue 1542)
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). Updated US...
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). Updated US guidelines
for treatment of VTE were published in 2016.
Idarucizumab (Praxbind) - An Antidote for Dabigatran
The Medical Letter on Drugs and Therapeutics • November 23, 2015; (Issue 1482)
The FDA has approved idarucizumab (Praxbind –
Boehringer Ingelheim) for urgent reversal of the
anticoagulant effect of the direct thrombin inhibitor
dabigatran etexilate (Pradaxa). Idarucizumab is...
The FDA has approved idarucizumab (Praxbind –
Boehringer Ingelheim) for urgent reversal of the
anticoagulant effect of the direct thrombin inhibitor
dabigatran etexilate (Pradaxa). Idarucizumab is the
first specific reversal agent to become available for
one of the new oral anticoagulants.